Published 2 days ago • loading... • Updated 1 day ago

DNA Immunotherapy Developer IMUNON Raises $9.75M to Advance Phase 3 Clinical Program

Summary by stocktitan.net

Clinical-stage biotech secures $3.25M upfront plus $6.5M in warrant potential to advance Phase 3 DNA immunotherapy development. See financing terms.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All

Left

Center

Right

ADKhabar

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants LAWRENCEVILLE, N.J., May 23, 2025 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that it has entered into definitive agreements for […]

1 day ago

Read Full Article